Elizabeth Arden Inc. has entered into an exclusive co-marketing agreement with Allergan Inc., a specialty pharmaceutical company and marketer in dermatology. Allergan is the maker of Botox Cosmetic, said to be the No. 1 non-surgical cosmetic procedure in the U.S. and M.D.Forte, a leading physician-dispensed skincare line in the U.S. The agreement teams Elizabeth Arden’s expertise in the prestige skincare industry with Allergan’s leadership in dermatology.

The partnership will result in a newly formulated PREVAGE launching at prestige cosmetic retailers worldwide through Elizabeth Arden. The new formulation will contain 0.5% idebenone, a patented, revolutionary, potent and effective antioxidant, according to Elizabeth Arden. The physician-strength product containing 1% idebenone will be known as PREVAGE MD and will continue to be sold by Allergan though physicians. PREVAGE was launched by Allergan in January 2005.

“The dermatology-inspired skincare market is experiencing explosive growth. The collaboration of Allergan, one of the world’s foremost specialty pharmaceutical companies, and Elizabeth Arden, a leader in innovative skincare since 1910, will bring PREVAGE and its breakthrough technology to the global skincare market,” said Scott Beattie, Chairman and chief executive of Elizabeth Arden. “We intend to take advantage of this opportunity and establish a leadership position in this category. We expect the collaboration to grow the dermatology-inspired skincare market globally.”

Elizabeth Arden and Allergan will collaborate on all aspects of PREVAGE, including formulation, packaging design, and marketing. The new formulation, created by Elizabeth Arden’s research and development team and Allergan’s scientists, will begin being distributed through leading department stores and prestige outlets worldwide in early 2006 and the physician product later in 2005. Elizabeth Arden and Allergan will also collaborate on developing additional PREVAGE products.